{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05630989",
            "orgStudyIdInfo": {
                "id": "PRO00045718"
            },
            "organization": {
                "fullName": "Medical College of Wisconsin",
                "class": "OTHER"
            },
            "briefTitle": "A Registry to Capture Patient Outcomes With KRAS G12R Altered Advanced Pancreatic Ductal Adenocarcinoma Treated With MEK Inhibitor-based Combination Therapy",
            "officialTitle": "A Registry to Capture Patient Outcomes With KRAS G12R Altered Advanced Pancreatic Ductal Adenocarcinoma Treated With MEK Inhibitor-based Combination Therapy",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "a-registry-to-capture-patient-outcomes-with-kras-altered-advanced-pancreatic-ductal-adenocarcinoma-treated-with-mek-inhibitor-based-combination-therapy"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-04",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-02-07",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-02",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-02",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-11-20",
            "studyFirstSubmitQcDate": "2022-11-29",
            "studyFirstPostDateStruct": {
                "date": "2022-11-30",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-04-10",
            "lastUpdatePostDateStruct": {
                "date": "2024-04-11",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR_INVESTIGATOR",
                "investigatorFullName": "Mandana Kamgar, MD",
                "investigatorTitle": "Assistant Professor",
                "investigatorAffiliation": "Medical College of Wisconsin"
            },
            "leadSponsor": {
                "name": "Mandana Kamgar, MD",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": false
        },
        "descriptionModule": {
            "briefSummary": "This is an observational precision oncology study designed to collect and analyze data that allows us to characterize the safety and efficacy of several different mitogen-activated protein kinase kinase inhibitor (MEKi) -based treatment strategies and the feasibility of administering MEKi combination therapies to patients with KRAS G12R mutated advanced pancreatic ductal adenocarcinoma (PDAC).",
            "detailedDescription": "Patient medical records, obtained both retrospectively and prospectively, will be examined for results of molecular profiling obtained through standard of care testing to help understand how well KRAS G12R pancreatic patients respond to MEKi-based combination matched therapy. Patient outcome parameters including but not limited to tumor response, patient survival, and toxicity will be analyzed. Moreover, metrics will be collected to ascertain whether a future clinical trial involving a MEKi-based combination therapy is feasible to carry out."
        },
        "conditionsModule": {
            "conditions": [
                "Pancreatic Ductal Adenocarcinoma"
            ],
            "keywords": [
                "Pancreatic Ductal Adenocarcinoma",
                "KRAS G12R mutation",
                "Precision medicine",
                "Retrospective Chart Review",
                "Prospective Chart Review"
            ]
        },
        "designModule": {
            "studyType": "OBSERVATIONAL",
            "patientRegistry": true,
            "targetDuration": "2 Years",
            "designInfo": {
                "observationalModel": "COHORT",
                "timePerspective": "OTHER"
            },
            "enrollmentInfo": {
                "count": 40,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Therapy with no MEKi",
                    "description": "Subjects have advanced PDAC with KRAS G12R mutation. Subjects' tumors must have KRAS G12R mutation, as determined by a next generation sequencing (NGS) panel or circulating tumor DNA panel of choice of the treating physician. Subjects will receive therapy with no MEKi.",
                    "interventionNames": [
                        "Other: combination therapy with no MEKi"
                    ]
                },
                {
                    "label": "Therapy with MEKi- Hydroxychloroquine (HCQ)",
                    "description": "Subjects have advanced PDAC with KRAS G12R mutation. Subjects' tumors must have KRAS G12R mutation, as determined by a next generation sequencing (NGS) panel or circulating tumor DNA panel of choice of the treating physician. Subjects will receive therapy with MEKi and HCQ.",
                    "interventionNames": [
                        "Drug: combination therapy with MEKi-HCQ"
                    ]
                },
                {
                    "label": "Therapy with MEKi- Epidermal growth factor receptor inhibitor (EGFRi)",
                    "description": "Subjects have advanced PDAC with KRAS G12R mutation. Subjects' tumors must have KRAS G12R mutation, as determined by a next generation sequencing (NGS) panel or circulating tumor DNA panel of choice of the treating physician. Subjects will receive combination therapy with MEKi and EGFRi.",
                    "interventionNames": [
                        "Drug: combination therapy with MEKi-EGFRi"
                    ]
                },
                {
                    "label": "Therapy with MEKi-Other",
                    "description": "Subjects have advanced PDAC with KRAS G12R mutation. Subjects' tumors must have KRAS G12R mutation, as determined by a next generation sequencing (NGS) panel or circulating tumor DNA panel of choice of the treating physician. Subjects will receive combination therapy with MEKi and a specified drug combination.",
                    "interventionNames": [
                        "Drug: combination therapy with MEKi."
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "OTHER",
                    "name": "combination therapy with no MEKi",
                    "description": "This cohort will receive combination therapy with no MEKi.",
                    "armGroupLabels": [
                        "Therapy with no MEKi"
                    ],
                    "otherNames": [
                        "mitogen-activated extracellular signal-regulated kinase inhibitor"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "combination therapy with MEKi-HCQ",
                    "description": "This cohort will receive combination therapy with MEKi-HCQ.",
                    "armGroupLabels": [
                        "Therapy with MEKi- Hydroxychloroquine (HCQ)"
                    ],
                    "otherNames": [
                        "mitogen-activated extracellular signal-regulated kinase inhibitor with hydroxychloroquine"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "combination therapy with MEKi-EGFRi",
                    "description": "This cohort will receive combination therapy with MEKi-EGFRi.",
                    "armGroupLabels": [
                        "Therapy with MEKi- Epidermal growth factor receptor inhibitor (EGFRi)"
                    ],
                    "otherNames": [
                        "mitogen-activated extracellular signal-regulated kinase inhibitor with epidermal growth factor receptor inhibitor"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "combination therapy with MEKi.",
                    "description": "This cohort will receive combination therapy with MEKi.",
                    "armGroupLabels": [
                        "Therapy with MEKi-Other"
                    ],
                    "otherNames": [
                        "mitogen-activated extracellular signal-regulated kinase inhibitor"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "The number of subjects with no progression.",
                    "description": "This is defined as the time from the start of treatment until six months on treatment, or disease progression, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, or death, whichever occurs first.",
                    "timeFrame": "6 months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "The number of subjects who have a complete response.",
                    "description": "A complete response will be determined using RECIST v1.1.",
                    "timeFrame": "2 years"
                },
                {
                    "measure": "The number of subjects who have a partial response.",
                    "description": "A partial response will be determined using RECIST v1.1.",
                    "timeFrame": "2 years"
                },
                {
                    "measure": "The number of grade 3 adverse events at least possibly related to a drug.",
                    "description": "Adverse events and serious adverse events will be classified using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.",
                    "timeFrame": "2 years"
                },
                {
                    "measure": "The number of grade 4 adverse events at least possibly related to a drug.",
                    "description": "Adverse events and serious adverse events will be classified using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.",
                    "timeFrame": "2 years"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n1. Age \u226518 years.\n2. Diagnosis of advanced pancreatic ductal adenocarcinoma as determined by the treating physician or tumor board.\n3. Tumor must have KRAS G12R mutation, as determined by a next generation sequencing (NGS) panel or circulating tumor DNA panel of choice of the treating physician.\n4. Ability to understand a written informed consent document and the willingness to sign it.\n\nExclusion Criteria:\n\n1. Age \\<18 years.\n2. Primary cancer diagnosis other than advanced pancreatic ductal adenocarcinoma\n3. Tumor does not have a KRAS G12R mutation.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ],
            "studyPopulation": "Subjects have advanced PDAC with KRAS G12R mutation.",
            "samplingMethod": "NON_PROBABILITY_SAMPLE"
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Mandana Kamgar, MD, MPH",
                    "role": "CONTACT",
                    "phone": "414-805-4600",
                    "email": "mkamgar@mcw.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Mandana Kamgar, MD, MPH",
                    "affiliation": "Medical College of Wisconsin",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Froedtert Hospital and the Medical College of Wisconsin",
                    "status": "RECRUITING",
                    "city": "Milwaukee",
                    "state": "Wisconsin",
                    "zip": "53226",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Mandana Kamgar, MD",
                            "role": "CONTACT",
                            "phone": "414-805-4600",
                            "email": "mkamgar@mcw.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 43.0389,
                        "lon": -87.90647
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000000230",
                    "term": "Adenocarcinoma"
                }
            ],
            "ancestors": [
                {
                    "id": "D000002277",
                    "term": "Carcinoma"
                },
                {
                    "id": "D000009375",
                    "term": "Neoplasms, Glandular and Epithelial"
                },
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M3585",
                    "name": "Adenocarcinoma",
                    "asFound": "Adenocarcinoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5534",
                    "name": "Carcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M12320",
                    "name": "Neoplasms, Glandular and Epithelial",
                    "relevance": "LOW"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000006886",
                    "term": "Hydroxychloroquine"
                },
                {
                    "id": "D000008934",
                    "term": "Mitogens"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000962",
                    "term": "Antimalarials"
                },
                {
                    "id": "D000000981",
                    "term": "Antiprotozoal Agents"
                },
                {
                    "id": "D000000977",
                    "term": "Antiparasitic Agents"
                },
                {
                    "id": "D000000890",
                    "term": "Anti-Infective Agents"
                },
                {
                    "id": "D000004791",
                    "term": "Enzyme Inhibitors"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000018501",
                    "term": "Antirheumatic Agents"
                },
                {
                    "id": "D000050258",
                    "term": "Mitosis Modulators"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M9940",
                    "name": "Hydroxychloroquine",
                    "asFound": "Suture",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11900",
                    "name": "Mitogens",
                    "asFound": "Corticotropin Injection",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4280",
                    "name": "Antimalarials",
                    "relevance": "LOW"
                },
                {
                    "id": "M4298",
                    "name": "Antiprotozoal Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4294",
                    "name": "Antiparasitic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4214",
                    "name": "Anti-Infective Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M7951",
                    "name": "Enzyme Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M20604",
                    "name": "Antirheumatic Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Infe",
                    "name": "Anti-Infective Agents"
                },
                {
                    "abbrev": "ARhu",
                    "name": "Antirheumatic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}